Artículos de revistas
Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia
Fecha
2015Autor
Luna Aguirre, Claudia Maribel
Martínez Fierro, Margarita de la Luz
Mar Aguilar, Fermín
Garza Veloz, Idalia
Treviño Alvarado, Víctor
Rojas Martínez, Augusto
Jaime Pérez, José Carlos
Malagon Santiago, Guadalupe Ismael
Gutiérrez Aguirre, César Homero
González Llano, Oscar
Salazar Riojas, Rosario
Hidalgo Miranda, Alfredo
Martínez Rodríguez, Herminia Guadalupe
Gómez Almaguer, David
Ortíz López, Rocío
Institución
Resumen
BACKGROUND: Acute lymphoblastic leukemia (ALL) is a highly diverse disease characterized by cytogenetic and molecularabnormalities, including altered microRNA (miRNA) expression signatures.
AIM: We perform and validate a plasma miRNA expression profiling to identify potential miRNA involved in leukemogenesis
METHODS: MiRNA expression profiling assay was realized in 39 B-ALL and 7 normal control plasma samples using TaqMan Low Density Array (TLDA) plates on Applied Biosystems 7900 HT Fast Real-Time PCR System. MiRNA validation was done for six miRNA differentially expressed by quantitative real-time PCR.
RESULTS: Seventy-seven circulating miRNA differentially expressed: hsa-miR-511, -222, and -34a were overexpressed, whereas hsa-miR-199a-3p, -223, -221, and -26a were underexpressed (p values < 0.005 for both sets). According to operating characteristic curve analysis, hsa-miR-511 was the most valuable biomarker for distinguishing B-ALL from normal controls,with an area under curve value of 1 and 100% for sensitivity, and specificity respectively.
CONCLUSIONS: Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL.